Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2008

View Archived Issues

Reduced ventricular tachycardia, fibrillation with celivarone in ICD patients

Elite presents update on abuse-resistant pain products

Dalcetrapib safe in phase II hyperlipidemia studies

Anisodamine attenuates slow reflow phenomenon after primary PCI

Efficacy successfully shown in phase III study of binodenoson for detecting ischemia

Novartis reports results from ALLAY study of Rasilez in left ventricular hypertrophy

Nymox releases new clinical data on its prostate drug NX-1207

Can-Fite enrolls first patient in phase IIb rheumatoid arthritis trial

ThromboGenics completes patient enrollment in phase IIb MIVI III trial of microplasmin

Cell Genesys and Takeda form global alliance for GVAX immunotherapy for prostate cancer

Acadia initiates second phase III trial of pimavanserin for Parkinson's disease psychosis

Cortex initiates enrollment in clinical trial of CX-717 in opiate induced respiratory depression

Cougar reaches agreement with FDA under SPA for phase III clinical trial of CB-7630

Repros reports interim safety results from study of Proellex in uterine fibroids

Amorcyte completes phase I stem cell therapy trial for acute myocardial infarction

Pfizer discontinues phase III CP-675,206 trial in advanced melanoma

Supratek's SP-1049C granted orphan drug designation for gastric cancer

AGI presents pharmacokinetic findings from arbaclofen clinical study

Positive efficacy results reported for istaroxime in acute heart failure

Sinovac receives China's approval for pandemic influenza H5N1 vaccine

Abraxis enrolls patients in phase II study of Coroxane in vascular disease prevention

FDA grants orphan drug designation to resveratrol formulation in MELAS syndrome

Novogen cardiovascular drug enters phase I clinical trial

Recent patents report novel agents for gastrointestinal disorders

New antidepressive agents reported in recent Lundbeck and NeuroSearch patents

Novel immunosuppressant agents disclosed in recent Actelion patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...